Protara Therapeutics Inc. (TARA)
NASDAQ: TARA
· Real-Time Price · USD
3.14
-0.01 (-0.32%)
At close: May 29, 2025, 2:31 PM
-0.32% (1D)
| Bid | 3.11 |
| Market Cap | 121.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -45.41M |
| EPS (ttm) | -1.49 |
| PE Ratio (ttm) | -2.11 |
| Forward PE | -1.85 |
| Analyst | Buy |
| Ask | 3.19 |
| Volume | 93,121 |
| Avg. Volume (20D) | 354,227 |
| Open | 3.17 |
| Previous Close | 3.15 |
| Day's Range | 3.13 - 3.19 |
| 52-Week Range | 1.59 - 10.48 |
| Beta | 1.72 |
About TARA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TARA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TARA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-18.52%
Protara Therapeutics shares are trading lower. The...
Unlock content with
Pro Subscription
1 month ago
+6.6%
Protara Therapeutics shares are trading higher after the company announced it will review the interim data from its Phase 2 ADVANCED-2 trial.
2 months ago · seekingalpha.com
Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial ResultsTARA's leading candidate is TARA-002, which so far looks like a promising immune-stimulating therapy derived from OK-432 (Picibanil). Their recent Phase 2 ADVANCED-2 trial also showed favorable result...